EPIX | ESSA Pharma Inc.

Healthcare | Biotechnology | Canada | NASD

Index	-	P/E	-	EPS (ttm)	-0.66	Insider Own	0.10%	Shs Outstand	44.09M	Perf Week	-1.96%
Market Cap	137.52M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	-83.97%	Shs Float	41.25M	Perf Month	11.11%
Income	-29.00M	PEG	-	EPS next Q	-0.20	Inst Own	78.90%	Short Float / Ratio	0.41% / 2.36	Perf Quarter	-9.09%
Sales	-	P/S	-	EPS this Y	16.70%	Inst Trans	-11.03%	Short Interest	0.17M	Perf Half Y	-7.69%
Book/sh	3.55	P/B	0.85	EPS next Y	-35.10%	ROA	-17.30%	Target Price	19.40	Perf Year	-45.45%
Cash/sh	3.42	P/C	0.88	EPS next 5Y	-	ROE	-17.60%	52W Range	1.40 - 5.92	Perf YTD	19.05%
Dividend	-	P/FCF	-	EPS past 5Y	23.70%	ROI	-	52W High	-49.32%	Beta	2.08
Dividend %	-	Quick Ratio	73.70	Sales past 5Y	-	Gross Margin	-	52W Low	114.29%	ATR	0.21
Employees	50	Current Ratio	73.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.50	Volatility	9.06% 7.53%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	35.00%	Profit Margin	-	Rel Volume	0.54	Prev Close	2.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	72.48K	Price	3.00
Recom	-	SMA20	2.08%	SMA50	3.49%	SMA200	6.80%	Volume	39,693	Change	2.39%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-21	Initiated	Piper Sandler	Overweight	$50
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$10 → $17
Nov-02-20	Initiated	Jefferies	Buy	$17
Oct-25-19	Initiated	Oppenheimer	Outperform	$8

Jun-01-23 07:00AM	ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (PR Newswire)
May-24-23 11:04AM	We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely (Simply Wall St.)
May-18-23 06:25AM	EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research)
May-11-23 07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (PR Newswire) +6.43%
07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (CNW Group)
07:19AM	Loading…
May-09-23 07:19AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (AP Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (CNW Group)
Apr-18-23 07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (CNW Group)
Apr-12-23 07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (PR Newswire) -5.82%
07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (CNW Group)
Mar-08-23 07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (CNW Group)
Mar-07-23 05:19AM	ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
05:43AM	Loading…
Feb-23-23 05:43AM	EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research)
Feb-13-23 05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (PR Newswire) +5.15%
05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (CNW Group)
Feb-07-23 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (CNW Group)
Feb-02-23 04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (PR Newswire) +6.52%
04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (CNW Group)
Jan-25-23 05:39AM	A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX) (Simply Wall St.) -5.50%
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Dec-21-22 05:07PM	Examining Penny Stocks with Technical Analysis (Investopedia) -5.91%
Dec-19-22 08:11AM	EPIX: Advancing Multiple Clinical Trials in 2023 (Zacks Small Cap Research)
Dec-15-22 08:30AM	We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate (Simply Wall St.) -5.02%
Dec-13-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 (CNW Group)
Nov-14-22 09:25AM	EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research) -7.90%
Nov-10-22 07:00AM	ESSA Pharma to Participate in Two Upcoming Investor Conferences (PR Newswire) +7.17%
11:13AM	Loading…
Oct-31-22 11:13AM	ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials (Benzinga) -18.37%
08:58AM	J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment (MarketWatch)
07:00AM	ESSA Provides an Update on its Clinical Collaboration with Janssen (CNW Group)
Oct-26-22 04:01PM	ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium (PR Newswire) +180.23%
07:00AM	Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat (CNW Group)
Sep-13-22 07:00AM	ESSA Pharma Appoints Philip Kantoff to its Board of Directors (CNW Group)
Aug-10-22 06:40AM	EPIX: Multiple Ongoing Studies of EPI-7386 (Zacks Small Cap Research)
Aug-04-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 (PR Newswire)
Jul-11-22 07:23AM	EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386 (Zacks Small Cap Research)
Jun-30-22 06:21PM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (CNW Group) -9.48%
Jun-28-22 06:29AM	ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer (Benzinga) -9.55%
Jun-27-22 04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (PR Newswire)
04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (CNW Group)
Jun-02-22 07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (PR Newswire) +5.64%
07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (CNW Group)
May-27-22 08:12AM	EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22 (Zacks Small Cap Research)
May-10-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (PR Newswire) +7.68%
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (CNW Group)
Apr-26-22 04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (CNW Group)
Apr-25-22 10:20AM	EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR (Zacks Small Cap Research)
Apr-08-22 01:00PM	ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders (CNW Group)
Mar-10-22 04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (PR Newswire)
04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (CNW Group)
Mar-09-22 11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (CNW Group)
Mar-08-22 04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (CNW Group)
Feb-04-22 05:16AM	EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research) +5.13%
Feb-03-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (CNW Group)
Jan-19-22 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) -6.80%
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Nov-22-21 09:20AM	EPIX: Combination Studies Set to Initiate (Zacks Small Cap Research)
Nov-18-21 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 (CNW Group)
Nov-08-21 07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences (PR Newswire)
07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences (CNW Group)
Oct-28-21 04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (CNW Group)
Oct-19-21 01:21PM	Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX) (Insider Monkey) +5.13%
Oct-07-21 10:25AM	ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact (Benzinga) +5.03%
09:00AM	ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 (CNW Group)
06:30AM	Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration (PR Newswire)
Aug-31-21 04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences (PR Newswire)
04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences (CNW Group)
Aug-24-21 06:30AM	EPIX: Unwarranted Selloff Following Phase 1 Trial Update (Zacks Small Cap Research) +6.93%
04:30AM	EPIX: Unwarranted Selloff Following Phase 1 Trial Update (Zacks Small Cap Research)
Aug-16-21 02:32PM	Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet (Benzinga) -34.48%
12:13PM	Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump (Benzinga)
10:22AM	Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August (Benzinga)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (CNW Group)
Jul-13-21 12:38PM	Hedge Funds Are Crazy About ESSA Pharma Inc. (EPIX) (Insider Monkey)
May-25-21 07:00AM	ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference (PR Newswire)
May-10-21 10:59AM	EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen (Zacks Small Cap Research)
May-06-21 07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 (PR Newswire)
07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 (CNW Group)
Apr-28-21 07:00AM	ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire) +7.20%
07:00AM	ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (CNW Group)
Apr-14-21 07:00AM	ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
07:00AM	ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference (CNW Group)
Apr-12-21 10:50AM	EPIX: Additional Preclinical Data Shows EPI-7386 Inhibits AR-Driven Transcription (Zacks Small Cap Research)
Apr-10-21 08:30AM	ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting (PR Newswire)
08:30AM	ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting (CNW Group)
Mar-26-21 04:05PM	ESSA Announces Change to its Board of Directors (PR Newswire)
04:05PM	ESSA Announces Change to its Board of Directors (CNW Group)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wood David S.	Chief Financial Officer	Dec 30	Buy	2.60	8,302	21,585	33,343	Jan 05 03:07 PM
Parkinson David Ross	Chief Executive Officer	Dec 30	Buy	2.60	3,067	7,974	56,542	Jan 05 06:18 PM
Parkinson David Ross	Chief Executive Officer	Dec 22	Buy	2.39	21,367	51,067	53,475	Jan 05 06:18 PM
BERGER FRANKLIN M	Director	Dec 21	Sale	2.41	72,223	174,401	684,404	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 20	Sale	2.53	43,617	110,351	756,627	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 16	Sale	2.67	50,000	133,500	800,244	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 15	Sale	2.88	82,000	235,800	850,244	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 14	Sale	3.00	25,000	75,000	932,244	Jan 05 03:41 PM
BIOTECH GROWTH N V	10% Owner	Oct 27	Buy	4.50	500,000	2,251,100	7,879,583	Oct 28 02:57 PM
BIOTECH GROWTH N V	10% Owner	Oct 26	Buy	3.98	1,500,000	5,968,500	7,379,583	Oct 28 02:57 PM
BIOTECH GROWTH N V	10% Owner	Jul 18	Buy	3.16	300,000	946,740	5,879,583	Jul 20 03:21 PM
BIOTECH GROWTH N V	10% Owner	Jul 15	Buy	3.13	241,665	756,798	5,579,583	Jul 18 12:48 PM
BIOTECH GROWTH N V	10% Owner	Jul 14	Buy	2.79	347,204	969,428	5,337,918	Jul 18 12:48 PM
Parkinson David Ross	Chief Executive Officer	Jun 30	Buy	2.96	4,887	14,456	32,108	Jul 05 01:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EPIX | ESSA Pharma Inc.

Upgrade your FINVIZ experience